| Theme | Therapeutic strategy for Crohn's disease -- Should mucosal healing be a final goal? | |
|---|---|---|
| Title | Enteral nutrition as new therapeutic strategy for Crohn's disease | |
| Publish Date | 2012/05 | |
| Author | Reiko Kunisaki | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Hiroto Kinoshita | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Tomohiko Sasaki | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Mao Matsubayashi | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Yoriko Murata | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Nobutaka Fujisawa | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Wataru Shibata | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Hideaki Kimura | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Shin Maeda | Department of Gastroenterology, Yokohama City University Graduate School of Medicine |
| [ Summary ] | In Japan, enteral nutrition (EN) has been the first line therapy for both active and quiescent Crohn's disease (CD). However now, the role of EN should be reassessed since immunosuppressants and biologicals are currently in use for patients with CD. Although the evidence level is not striking, the available data suggest that EN may benefit patients with CD, especially those with small bowel involvement. EN is effective for CD in children and adolescents, in whom it may be employed to induce remission, irrespective of disease location. EN is also regarded as being appropriate for adjunctive treatment to support nutrition and as a primary therapy for patients with intestinal stenosis or short bowel syndrome. There are fewer side effects with this treatment than with drug therapies. More prospective studies looking at the impact of concomitant EN on clinical outcomes in patients with CD should be conducted. | |